Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Stem Cells in Drug Discovery 2015


Disease Modeling and Phenotypic Drug Screening for Diabetic Cardiomyopathy Using Human Induced Pluripotent Stem Cells

Faye Drawnel, Scientist, Pharma Research and Early Development, Roche

Diabetic cardiomyopathy is a complication of type 2 diabetes, with known contributions of lifestyle and genetics. Here, environmentally and genetically driven in vitro models of the condition are developed using human induced pluripotent stem cell-derived cardiomyocytes. First, diabetic clinical chemistry is mimicked to induce a phenotypic surrogate of diabetic cardiomyopathy, generating structural and functional disarray. Next, genetic effects are modelled by deriving cardiomyocytes from 2 diabetic patients with variable disease progression. The cardiomyopathic phenotype is recapitulated in the patient-specific cells basally, with a severity dependent on their original clinical status. These models are incorporated into successive levels of a screening platform, identifying drugs which preserve cardiomyocyte phenotype in vitro during diabetic stress. In this work, the first patient-specific iPSC model of a complex metabolic condition is presented, showing the power of this technique for discovery and testing of therapeutic strategies for a disease with ever-increasing clinical significance.

Add to Calendar ▼2015-06-02 00:00:002015-06-03 00:00:00Europe/LondonStem Cells in Drug Discovery 2015Stem Cells in Drug Discovery 2015 in